Original Article
Patient Perceptions of Oseltamivir for the Treatment of Influenza
Abstract
Objectives: Oseltamivir (Tamiflu) is approved by the Food and Drug Administration and is advertised for the treatment of influenza types A and B. Patient perceptions of its efficacy have not been adequately studied. Recent systematic reviews have called the benefits of this drug into question relative to the cost and adverse effect profile. We hypothesized that most people would be unaware of the efficacy, cost, or adverse effect profile of the drug. Our objective was to determine patient perceptions of efficacy, cost, and adverse effect profile of oseltamivir for the treatment of influenza.Methods: This was a cross-sectional, multiple-choice, open-response survey of adult patients and adult caregivers of pediatric patients who presented to the emergency department (ED) with flu-like symptoms. Flu-like symptoms were defined as any respiratory symptom plus fever or body aches. The study took place during the 2014–2015 flu season at a rural ED. We analyzed the data, with descriptive statistics reported as frequencies/percentages for categorical data. Survey data collected as Likert scale data were summarized using mean, median, and mode.
Results: During the 4-month period, 70 surveys were completed. A total of 67% of the participants were women, with 84% younger than 40 years. Subjects younger than 40 years were more likely to have seen advertising for oseltamivir (31% vs 0%, P = 0.04). Less than half reported having received the flu vaccine that year. Most reported that oseltamivir was an effective treatment for the flu. Most overstated the perceived efficacy of oseltamivir. Most were not willing to take the medication if it had adverse effects, with the most deterring adverse effects being potential kidney and liver injury.
Conclusions: In our study most patients reported overly positive expectations for the efficacy of oseltamivir for treating influenza. Most reported that commonly listed adverse effects would deter their use of the medication.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010;59:1057-1062.
2. Schanzer DL, Schwartz B. Impact of seasonal and pandemic influenza on emergency department visits, 2003-2010, Ontario, Canada. Acad Emerg Med 2013;20:388-397.
3. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086-5096.
4. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45:1568-1575.
5. Yang SG, Cao B, Liang LR, et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One 2012;7:e29652.
6. Wang CB, Chiu ML, Lin PC, et al. Prompt oseltamivir therapy reduces medical care and mortality for patients with influenza infection: an Asian population cohort study. Medicine (Baltimore) 2015;94:e1070.
7. Centers for Disease Control and Prevention. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 2006;55:44-46.
8. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006;295:891-894.
9. Ortiz JR, Kamimoto L, Aubert RE, et al. Oseltamivir prescribing in pharmacy-benefits database, United States, 2004-2005. Emerg Infect Dis 2008;14:1280-1283.
10. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545.
11. Torjesen I. Cochrane review questions effectiveness of neuraminidase inhibitors. BMJ 2014;348:g2675.
12. Zgierska A, Miller M, Rabago D. Patient satisfaction, prescription drug abuse, and potential unintended consequences. JAMA 2012;307:1377-1378.
13. Fenton JJ, Jerant AF, Bertakis KD, et al. The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch Intern Med 2012;172:405-411.
14. Tak HJ, Ruhnke GW, Meltzer DO. Association of patient preferences for participation in decision making with length of stay and costs among hospitalized patients. JAMA Intern Med 2013;173:1195-1205.
15. Svensson S, Kjellgren KI. Adverse events and patients' perceptions of antihypertensive drug effectiveness. J Hum Hypertens 2003;17:671-675.
16. Espay AJ, Norris MM, Eliassen JC, et al. Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology 2015;84:794-802.
17. Shrank WH, Cox ER, Fischer MA, et al. Patients' perceptions of generic medications. Health Aff (Millwood) 2009;28:546-556.
18. Singh S, Barghoorn J, Bagdonas A, et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Investig 2003;23:561-569.
19. Ashworth M, White P, Jongsma H, et al. Antibiotic prescribing and patient satisfaction in primary care in England: cross-sectional analysis of national patient survey data and prescribing data. Br J Gen Pract 2016;66:e40-e46.
20. Taubman SL, Allen HL, Wright BJ, et al. Medicaid increases emergency-department use: evidence from Oregon' health insurance experiment. Science 2014;343:263-268.
